All questions are shown as received by the Trust.
Q1. How many patients were treated in the past 6 months (for any disease) with:
• Ruxolitinib
• Fedratinib
Q2. Does your trust treat myeloproliferative neoplasms? If not, which other trust do you refer these patients to?
Q3. Please provide the total number of patients treated in the last 6 months for:
• Polycythaemia Vera (ICD10 code D45)
• Myelofibrosis (ICD10 code D47.4)
• Myelofibrosis (ICD10 code D47.4) patients aged 65 and older
Q4. Of the patients treated in the past 6 months with Ruxolitinib, how many patients had a diagnosis for:
• Polycythaemia Vera (ICD10 code D45)
• Myelofibrosis (ICD10 code D47.4)
Q5. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
• Of the patients diagnosed with myelofibrosis in the past 3 years, how many were treated in the past 6 months with Hydroxycarbamide?
• Of the patients diagnosed with myelofibrosis in the past 3 years, how many were treated in the past 6 months with Interferon therapy?
• Of the patients diagnosed with myelofibrosis in the past 3 years, how many have received no active treatment in the past 6 months?
